Placental isoferritin levels in pregnant patients with systemic lupus erythematosus and/or antiphospholipid syndrome.
OBJECTIVE
Low serum placental isoferritin (PLF), an immunosuppressive cytokine-like protein, was found in women with underlying placento-vascular dysfunction, such as intrauterine growth retardation and preeclamptic toxemia. The possible contribution of this placental product in the assessment of pregnant patients with either systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) was investigated.


METHODS
Seventy-five healthy pregnant women used as controls and 25 preselected pregnant patients with either SLE and/or APS were enrolled in the study. Study patients were in remission during conception and all patients agreed to give 5 ml of venous blood at midgestation. The samples were frozen and analyzed retrospectively. After delivery, pregnancy outcomes were gathered from hospital records.


RESULTS
Seventeen (68%) women had uneventful pregnancies and deliveries (normal) whereas 8 (32%) showed pathologic obstetric outcomes. Mean midgestational serum PLF levels were similar in the control and normal outcome groups (87 U/ml), whereas significantly lower levels (37 U/ml) were measured in the pathologic outcome group. Using a cutoff level of 10 U/ml, 85% from the normal outcome group and 15% from the pathologic outcome group were above this threshold level, with 60% specificity and 100% sensitivity.


CONCLUSIONS
These preliminary data suggest that PLF values may reflect placento-vascular functions. These may represent a predictive biomarker for developing obstetric complications in pregnant women with either SLE and/or APS.
Maymon
R
R
Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Bar
J
J
Sherman
D
D
Moroz
C
C
D000328:Adult; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000276:immunology*; D005260:Female; D005293:Ferritins / Q000032:analysis*; D006801:Humans; D007166:Immunosuppressive Agents / Q000032:analysis*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology*; D010920:Placenta / Q000737:chemistry*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology*; D011256:Pregnancy Outcome; D012189:Retrospective Studies
D007166:Immunosuppressive Agents; D005293:Ferritins